How to Use This Book

This book was produced after countless hours of studying, note taking, cross-referencing numerous sources, and multiple cups of coffee. This book truly contains all the essential information you must know. You may at times ask yourself if you really need to know some of the information contained in this book. The answer to that question is yes, without a doubt! This is not a book you can read once and regurgitate. Repeated exposure and understanding of the study material within these pages is essential. I would not claim that this book contains absolutely everything you will see on the certification exam. But I will promise that if you truly know all the material in this book, you will have the best opportunity to pass the board examination and will become a better physician in the process.

There are 85 chapters in this book. I would recommend that you review each chapter at least three times. Begin each day by reading a chapter and taking notes or making up practice questions based on each section of the chapter. If you resort to highlighting, you may find yourself highlighting entire pages so I would refrain from that specific study technique. At the end of your study session, review your notes or the study questions you’ve come up with, and then go back and review the contents of the chapter you read the day before. If you study one chapter per day, and review the book in its entirety three times, you will require approximately 255 days (that’s about nine months!) so do not procrastinate. True understanding of this material is essential if you wish to pass the board certification examination.

Once you have passed the written examination, utilize the core knowledge in this book to prepare yourself for the oral board examination. If you would like to learn specific techniques in memory enhancement, oral presentation skills, or utilize practical cases designed to assess your knowledge and prepare you for the oral board examination I would recommend using Preparing for the Anesthesia Oral Board Exam, which can be obtained at www.BeyondAnesthesia.com. This book will teach you techniques that will help you prepare for and master the oral board examination as administered by the ABA. Now, let us get started…
1. In order to better understand pulmonary physiology, it is important to understand pulmonary blood flow and how it affects gas exchange. The image below illustrates the three major lung zones and the relative distribution of ventilation to perfusion in each zone:

- **Zone I**: ventilation exceeds perfusion leading to Dead Space
  - PA > Pa > Pv

- **Zone II**: ventilation and perfusion are approximately matched!
  - Pa > PA > Pv

- **Zone III**: perfusion exceeds ventilation leading to Shunt!
  - Pa > Pv > PA

- **Zone IV**: Pa > P_{IS} > Pv > PA

2. Zone I is the uppermost lung zone and it is the collapse zone where alveolar pressure (P_{A}) is greater than arterial pressure (Pa) and venous pressure (Pv). This is an example of dead space where the lung is ventilated but not adequately perfused. Zone II is the waterfall region where arterial pressure exceeds alveolar pressure, which in turn exceeds venous pressure. Zone III illustrates distention where both arterial and venous pressures exceed the alveolar pressure. Zone IV is the lowest region in the lung and shows arterial pressure to be the greatest, followed by interstitial pressure (P_{IS}), then venous pressure, and finally alveolar pressure. This is an example of a “shunt” where the lung is perfused but not adequately oxygenated. In a sitting patient, ventilation is greatest in the upper lung field (zone 1) while perfusion is greatest in the lowest lung field (zone 3). This is very important since zone 1 essentially creates what is called “dead space.”
space”, an area that is ventilated but not perfused. Zone 3 and 4 on the other hand create a “shunt”, an area that is perfused but not well ventilated.

3. Dead space (designated as Vd/Vt) is the fraction of the normal tidal volume that does not participate in gas exchange. Dead space is created when there are areas of the lung that are ventilated but not perfused (think pulmonary embolus). Vd/Vt is characterized by the equation \((\text{PaCO}_2 - \text{PETCO}_2) / \text{PaCO}_2\). Normal dead space is considered to be 0.3 L (300cc).

   a. In general, any factor that increases pulmonary vascular resistance or increases alveolar pressure will increase pulmonary dead space volume. Some examples include:
      i. Positive pressure ventilation (\(↑\text{PA}\))
      ii. PEEP/ CPAP (\(↑\text{PA}\))
      iii. Bronchodilation (\(↑\text{anatomic dead space}\))
      iv. Low cardiac output (reduced pulmonary blood flow and increased PVR)
      v. PE

   b. Dead space also increases with age, anticholinergics (atropine), upright position, smoking, emphysema, and any factor that may decrease pulmonary perfusion including hypovolemia, hypotension, and hypothermia.

4. Hypoxic pulmonary vasoconstriction (HPV) is a physiologic response adapted towards decreasing pulmonary shunting. As stated earlier shunting occurs when there is ventilation to perfusion mismatch. Any area that is perfused but not ventilated is a “shunt” whereas areas that are ventilated but not perfused are called “dead space”. An example of a shunt would be a pneumothorax (lung is perfused but not ventilated); while an example of dead space would be a pulmonary embolus (which is an area of the lung that is ventilated but not perfused).

   a. HPV is reduced in the presence of PEEP, acidosis, alkalosis, hypocapnia, hypothermia, calcium channel blockers, high frequency ventilation, sodium nitroprusside, nitroglycerin, and isoproterenol. HPV is reversed by elements that cause distention of pulmonary vessels including elevated PA pressures, mitral stenosis, volume overload, hypothermia, vasoactive drugs, and pulmonary embolism. HPV is inhibited by volatile anesthetics as well as nitrous oxide.

   b. HPV is increased if the mixed venous O2 is equal or less than 30 mmHg.

5. Shunt fraction (designated as Qs/Qt) is within 5-10% under normal circumstances. If Qs/Qt increases to above 30%, increases in FiO2 will no longer increase the PaO2.

   a. Normal pulmonary shunting is approximately 10%; this implies that 90% of the cardiac output participates in gas exchange. Some causes of pulmonary shunting including pneumothorax, bronchospasm, and right to left cardiac shunts.

   b. As illustrated below, as PaO2 decreases, the shunt fraction (Qs/Qt) increases. The PaCO2 does not begin to increase until the shunt fraction reaches 50%.

![Graph showing relationship between PaO2, PaCO2, and Qs/Qt](image-url)
c. \( \text{PaO}_2 \) increases by 50 mmHg for each 10% increase in \( \text{FiO}_2 \). Therefore, a \( \text{FiO}_2 \) of 0.2 is equivalent to a \( \text{PaO}_2 \) of 100 mmHg, while a \( \text{FiO}_2 \) of 1.0 (100% oxygen) is equivalent to a \( \text{PaO}_2 \) of 500 mmHg. Hence, in the absence of a shunt and with a normal A-a gradient, a patient on 100% oxygen should have a \( \text{PaO}_2 \) of 500 mmHg.

d. Since our lungs are not perfectly efficient there exists a “normal” Alveolar-arterial oxygen gradient (A-a gradient). This gradient is approximately 5-10 mmHg on room air and 20-30 mmHg when on 100% oxygen. Overall, one can approximate a normal A-a gradient to be \( \frac{1}{4} \) of a patient’s age.

e. The A-a gradient is important when determining the etiology of hypoxemia in a patient. Hypoxemia due to hypoventilation and low \( \text{FiO}_2 \) do not affect the A-a gradient. On the other hand, ventilation-perfusion mismatch, right to left shunting, and decreased DLCO all cause an increase in the A-a gradient.

i. The A-a gradient is also increased in patients undergoing a general anesthetic due to the following reasons:

1. Decreased cardiac output leads to decreased lung perfusion, resulting in greater dead space ventilation and V/Q mismatch.
2. Decreased FRC under general anesthesia leads to decreased pulmonary compliance and ventilation-perfusion mismatch. (The decrease in FRC is greatest 3-5 days post surgery and lasts for 10-14 days postoperatively).
3. Decreased lung and chest wall compliance further aggravates V/Q mismatch.
4. Increased airway resistance contributes to ventilation and perfusion mismatch.
5. Paralysis worsens V/Q mismatch. In a paralyzed supine patient, ventilation is greatest anteriorly in the non-dependent portion of the lung (due to positive pressure ventilation) while perfusion is greatest posteriorly in the dependent portion of the lung (due to gravity). On the other hand an awake spontaneously breathing supine patient has greater ventilation and perfusion in the dependent portion of the lung.

ii. Other factors increasing the A-a gradient include: (mnemonic: Smoking Adolescents Avoid Cops)

1. Smoking
2. Advanced age
3. Atelectasis (obesity, pregnancy, hypoventilation)
4. COPD

f. Pulmonary blood flow is dependent on gravity, alveolar pressure, and pulmonary vascular resistance. Perfusion is greatest in the dependent regions of the lung where the gravitational pull is strongest. Hence a supine patient will have a different perfusion/ventilation ratio in the same region of the lung as compared to a patient in the sitting posture. If alveolar pressure (P_a) exceeds arterial pressure (Pa) as occurs in Zone 1, the increase in pulmonary vascular resistance diverts blood flow to areas of lesser alveolar pressure (Zones 2 and 3). Since increased pulmonary vascular resistance results in a reduction in pulmonary blood flow it is important to know some of the physiologic factors that can increase pulmonary vascular resistance: (mnemonic: Hairy Armpits Have Lousy Hygiene):

i. Hypoxia: leading to hypoxic pulmonary vasoconstriction
ii. Acidosis
iii. Hypercarbia: leads to reactive vasoconstriction
iv. Low cardiac output: low vascular flow increases vascular resistance
v. Hypothermia

7. The distribution of pulmonary ventilation is highly dependent on gravity, pulmonary compliance, and airway resistance. As one moves distally in the pulmonary tree, the cross sectional area
increases rapidly and resistance to flow (airway resistance) decreases. Pulmonary compliance describes the change in volume that occurs as a change in pressure is applied to the lungs or the chest wall. Compliance can be affected by factors such as obesity, and pulmonary fibrosis. Gravity is a major determinant of pulmonary ventilation. Irrespective of patient position (supine or lateral decubitus), during spontaneous ventilation the alveoli in the dependent pulmonary region are more compliant (experience a greater change in volume per unit change in pressure) as compared to apical alveoli and hence a greater fraction of the ventilation occurs in the dependent portion of the lung. On the other hand, in an anesthetized but spontaneously breathing patient, atelectasis and hypoventilation will favor the non-dependent portion of the lungs. Similarly, during mechanical ventilation compliance and resistance favor ventilation of the non-dependent regions of the lung.

8. Airway resistance and pulmonary compliance also affect the work of breathing. The work of breathing is increased with increased airway resistance and decreased pulmonary compliance. Hence, patients with obstructive lung disease (increased airway resistance) will increase their work of breathing by rapid shallow breaths, while those with a restrictive lung disease (poorly compliant lung or chest wall) will increase their work of breathing by taking slow deep breaths.

9. Spirometry is a technique used to assess pulmonary function. Spirometric measurements help determine lungs capacities and volumes. The image below indicates the relationship of some of these parameters:

![Spirometry Image]

a. Closing capacity (CC) consists of closing volume (CV) and residual volume (RV). Closing capacity is the volume where small airways begin to close and collapse. Shunting occurs when closing capacity exceeds functional residual capacity (FRC).

b. Closing capacity increases with chronic bronchitis, left ventricular failure, obesity, smoking, surgery, and extreme age (mnemonic: CLOSE).

c. FRC is the point at which the elastic recoil of the lung equals the recoil of the chest wall. FRC is increased in the elderly, severe emphysema, application of PEEP, and asthma due
to air trapping. FRC is decreased in neonates, general anesthesia, supine posture, obesity, ascites, and pregnancy (mnemonic: NG SOAP).
   i. Abdominal and thoracic surgery decrease FRC for several days post operatively.
   ii. Under anesthesia, loss of thoracic muscle tone decreases elastic recoil of the chest wall and results in a decrease in FRC. This reduction is worsened in the supine position as the relaxed diaphragm migrates cephalad.
   iii. Note that FRC and RV are the two values not measured by spirometry.

d. A sensory block above the T6 level can lead to a decrease in expiratory reserve volume (ERV) and hence a reduction in FRC.

e. Normal vital capacity is 50cc/kg. Normal pulmonary compliance (change in volume per applied pressure) is 200cc/cm H2O.

f. Obstructive lung diseases (emphysema, asthma, chronic bronchitis) are characterized by decreased flow where FEV1 is decreased while FVC remains largely normal resulting in a decreased ratio of FEV1/FVC. Restrictive lung diseases (pulmonary fibrosis, obesity, pregnancy) are characterized by a decrease in volume but flows remain the same hence the ratio of FEV1/FVC remains normal.

g. The table below indicates some normal values associated with each pulmonary parameter:

<table>
<thead>
<tr>
<th>Test</th>
<th>Average “normal” value</th>
</tr>
</thead>
<tbody>
<tr>
<td>TLC</td>
<td>5-6 (L)</td>
</tr>
<tr>
<td>VC</td>
<td>4-5 (L)</td>
</tr>
<tr>
<td>FEV1</td>
<td>3-4 (L)</td>
</tr>
<tr>
<td>% FVC1</td>
<td>80</td>
</tr>
<tr>
<td>FRC</td>
<td>2-4 (L)</td>
</tr>
</tbody>
</table>

10. Flow-volume loops are utilized when one needs to determine the presence and severity of airway obstruction. The image below illustrates a normal flow-volume loop:

**Normal Flow-Volume Loop**
a. As illustrated by the image, the patient performs a forced vital capacity maneuver in expiration and inspiration which allows the following spirograph to be charted. The y-axis illustrates flow rate in liters/sec while the x-axis illustrates volume in liters. The pleural pressure is negative in the inspiratory phase and positive in the expiratory phase.

b. The following flow-volume loops illustrate some of the disease processes that can be determined through this method. The dashed lines illustrate a normal loop while the solid lines show the abnormal curve:

![Examples of Flow-Volume Loops](image)

Expiratory
Inspiration

A B C D E

c. Can you determine which disease process is shown in each of the above flow-volume loops?

i. Image (A) illustrates a limited inspiratory and expiratory phase with a shift to the right indicating a reduced TLC. This is an example of a restrictive lung disease such as pulmonary fibrosis, scoliosis, or obesity.

ii. Image (B) illustrates a reduced inspiratory and expiratory phase without changes to the TLC. This is indicative of a fixed defect such as a tracheal web, stricture, or goiter and is the most common flow-volume loop.

iii. Image (C) illustrates a reduced inspiratory phase with a normal expiratory phase. If you consider a “ball-valve” effect where the ball obstructs the opening once pressure is applied to it, then one can deduce that this is an extrathoracic defect such as sleep apnea, or vocal cord palsy.

iv. Image (D) illustrates a normal inspiratory phase followed by a reduced expiratory phase. Again, the “ball-valve” is causing obstruction in the expiratory phase hence this is most likely an intrathoracic defect such as a bronchial tumor.

v. Image (E) illustrates a severe reduction in both phases of the breathing cycle and a reduction in the FVC. This is indicative of a diffuse obstructive defect such as COPD or asthma.

11. Oxygen delivery to tissues is determined by cardiac output, total oxygen content of blood, and the type of hemoglobin present (ex: fetal hemoglobin levels are increased in sickle cell anemia, and β thalassemia). As you may recall, cardiac output is demonstrated by the formula heart rate multiplied by stroke volume. Oxygen content (CaO₂) is influenced by the number of hemoglobin molecules and their saturation, recall the formula: (0.003 x PaO₂) + (1.34 x Hgb x SaO₂). Although oxygen exists in blood as a dissolved and a bound form, the bound hemoglobin has the greatest contribution to oxygen content. The first portion of the above formula represents the dissolved portion of oxygen in blood. As atmospheric pressure increases, and temperature decreases, more oxygen is forced into solution (dissolved). The second portion of the equation represents the bound portion of oxygen and illustrates that each gram of hemoglobin carries 1.34 ml of oxygen when fully saturated which is why the oxygen saturation expressed as a percentage is included in the formula. Hence, one way to increase oxygen delivery is to increase cardiac output. Another way is to increase the number of hemoglobin molecules and their saturation by supplying 100% oxygen. This concept can be carried forward when attempting to determine the factors which influence mixed venous oxygen saturation. If one thinks critically and understands
the physiology of our cardiovascular system then the following conclusion can be derived: the venous oxygen saturation is determined by the two factors influencing supply which are cardiac output and oxygen content, and the factor influencing demand which is oxygen consumption (which can be affected by a variety of things including metabolic rate).

12. It is essential to understand the behavior of hemoglobin with respect to oxygen carrying capacity as demonstrated by the oxyhemoglobin dissociation curve (OHDC).

![OHDC Diagram]

- **a.** The above diagram illustrates that at a partial pressure of 27 mmHg, the hemoglobin molecule will be 50% saturated. This is referred to as the “P50”. The P50 for neonates is 19 mmHg indicating a left shift of the OHDC, and the P50 for children is 30 mmHg which indicates a right shift of the OHDC.
- **b.** OHDC shifts to the right when there is an increase in PCO2, H+ (acidosis), temperature, 2,3 DPG (seen in anemia, cirrhosis, or increased altitude), and sickle cell hemoglobin. If there is a right shift of the OHDC then at the same partial pressure of oxygen, the hemoglobin molecule will be less saturated (oxygen molecules will have been released from the binding sites). Another way to think about this would be to say that the hemoglobin molecule would have to have a higher PaO2 in order to maintain the same level of saturation. In short, remember “Right Releases!”
- **c.** OHDC shifts to the left with decreases in PCO2, H+, temperature, 2,3 DPG, and in the presence of fetal hemoglobin, methemoglobin, and carboxyhemoglobin. A left shift results in the hemoglobin molecule maintaining its binding to the oxygen molecules and maintaining its saturation despite a lower partial pressure of Oxygen. Hence, “Left Lasts!”
- **d.** Chronic anemia can affect oxygen delivery by causing an elevation in 2,3 DPG, P50, cardiac output (due to tachycardia), coronary blood flow (due to decreased viscosity), and oxygen extraction (lowering mixed venous O2).
- **e.** The Bohr effect states that the OHDC shifts with changes in PCO2.
- **f.** The Haldane effect states that deoxygenated hemoglobin can carry more CO2.
- **g.** The factors that affect the OHDC are presented in the table below. Note that a “raise” in the value of these factors creates a right shift and that “lowering” of the factors creates a left shift.
<table>
<thead>
<tr>
<th>Left shift- “lower”</th>
<th>Right shift- “raise”</th>
</tr>
</thead>
<tbody>
<tr>
<td>↓H⁺ concentration</td>
<td>↑H⁺ concentration</td>
</tr>
<tr>
<td>↓Temperature</td>
<td>↑Temperature</td>
</tr>
<tr>
<td>↓2,3 DPG</td>
<td>↑2,3 DPG</td>
</tr>
<tr>
<td>Fetal hemoglobin</td>
<td>Pregnancy, chronic anemia</td>
</tr>
<tr>
<td>Carboxyhemoglobin and methemoglobin</td>
<td>Sickle cell hemoglobin</td>
</tr>
</tbody>
</table>

h. One shortcut to remember when considering the partial pressure of oxygen with respect to hemoglobin oxygen saturation are the numbers “456789” which stand for…

<table>
<thead>
<tr>
<th>PaO₂</th>
<th>SpO₂ %</th>
</tr>
</thead>
<tbody>
<tr>
<td>40</td>
<td>70</td>
</tr>
<tr>
<td>50</td>
<td>80</td>
</tr>
<tr>
<td>60</td>
<td>90</td>
</tr>
</tbody>
</table>

13. The CO₂ response curve is also important to understand since it too affects the cardiovascular and the respiratory system:

a. The CO₂ response curve is linear when the PCO₂ is between 20 to 80 mmHg. As the PCO₂ increases above 40 mmHg, the minute ventilation (MV) also increases until the PCO₂ reaches 100 mmHg. Above 100 mmHg CO₂ acts as a respiratory depressant and actually decreases respiratory drive. Very high levels of narcotics as well as volatile anesthetics depress the response curve such that elevations in PCO₂ create a very small change in MV (illustrated by the dashed line above).

b. The CO₂ response curve shifts to the left (implying increased sensitivity to CO₂) in hypoxia, anxiety, elevated intracranial pressure, cirrhosis, and acidemia. The curve shifts to the right (decreased sensitivity to CO₂) in metabolic alkalosis, during normal sleep, when influenced by drugs such as narcotics, catecholamines, salicylates, and aminophylline, and when there is denervation of the peripheral chemoreceptors.
14. Peripheral chemoreceptors adjust the ventilatory response to hypoxemia. When the PaO₂ falls below 60 mmHg (equivalent to an oxygen saturation of 90%) the peripheral chemoreceptors in the carotid and aortic bodies initiate an increase in minute ventilation in order to increase the partial pressure of oxygen in the blood. This is not to be confused with the carotid baroreceptors which respond to changes in aortic blood pressure.

15. Central receptors respond to changes in pH and PaCO₂. Once a change is detected, within a minute the central receptors create a response which includes increases in respiratory rate and tidal volume in order to restore normal physiologic parameters. This response is modulated via the medulla and cranial nerves IX and X.

16. Pulmonary hypertension is defined as pulmonary artery pressure of 30 mmHg or greater. Pulmonary hypertension can occur due to a multitude of etiologies including:
   a. Increased pulmonary blood flow (ex: left to right shunt)
   b. Increased pulmonary vascular resistance (PVR). Recall that PVR = (mean PA – PCWP)/CO x 80 with normal values being 100-150 dynes/sec/cm. Several factors can increase the PVR and should be stored to memory. These include hypoxia, hypercarbia, acidosis, and damage or destruction of pulmonary vessels (mnemonic: Hunters Have Active Dogs). Vascular damage can occur secondary to:
      i. Increased valvular pressures due to mitral stenosis or regurgitation.
      ii. Pulmonary embolus including fat, air, and amniotic fluid emboli.

17. Treatment for pulmonary hypertension relies on understanding and addressing the underlying etiology. Assuming that hypoxia, and hypercarbia have been addressed, further treatment for pulmonary hypertension includes vasodilators such as inhaled nitric oxide (20-40 ppm), calcium channel blockers, nitroglycerin, and PGE₁ agonists such as alprostadil.

18. Pulmonary hypertension can lead to pulmonary edema. Pulmonary edema also occurs due to cardiogenic and non-cardiogenic causes. Cardiogenic etiologies include factors that increase capillary pressures such as mitral stenosis, congestive heart failure, and fluid retention. Non-cardiogenic etiologies include factors that increase capillary leak including negative pressure pulmonary edema, aspiration, ARDS, DIC, burns, sepsis, neurogenic edema, decreased oncotic pressure, and lymphatic obstruction.
   a. Cardiogenic pulmonary edema can be diagnosed via elevated pulmonary capillary wedge pressures (PCWP), pink frothy sputum and secretions, and patchy infiltrates on chest x-ray.
   b. Non-cardiogenic pulmonary edema can be diagnosed via low PCWP, and consideration of underlying etiologies such as sepsis, DIC, smoke inhalation, and massive blood transfusions.
   c. Treatment includes 100% oxygen, application of PEEP, preload reduction with vasodilators such as nitroglycerin (NTG), diuretics, and enhancement of cardiac output and contractility using inotropes.

19. How does smoking affect general anesthesia?
   a. Smoking increases airway irritability and secretions; it also raises closing capacity above FRC which results in shunting and hypoxia. Furthermore, nicotine increases sympathetic tone.
   b. Smoking cessation should take place 8 weeks (2 months) prior to the administration of a general anesthetic for maximal benefits. If stopped one day prior to the operation it will decrease the carboxyhemoglobin levels and begin a correction of the left shift of the OHDC. Cessation one week prior to the anesthetic can aid in diminishing of the pulmonary secretions.
   c. Carboxyhemoglobin in smokers can be as high as 10-15% (as identified by cooximetry since a dual wave pulse oximeter will interpret carboxyhemoglobin as oxyhemoglobin).

20. Under normal physiologic conditions 250 cc/min of oxygen is absorbed from the alveoli while 200 cc of CO₂ is produced per minute. Apneic oxygenation is a method through which a
continuous inflow of oxygen into the lungs provides for passive exchange of oxygen for carbon dioxide. As the alveolus fills with CO₂, less space is left in the alveolus to be occupied by oxygen. Hence, apneic oxygenation is limited by the starting level of PaCO₂ and the amount of PaCO₂ produced. PaCO₂ increases by 6 mmHg for the first minute and 3 mmHg each subsequent minute. Furthermore, incomplete de-nitrogenation and low FRC can further decrease the available reservoir for oxygen. Eventually, as the PaCO₂ levels rise, active ventilation will need to take place or cardiac arrhythmia ensues.
**Index**

<table>
<thead>
<tr>
<th>A</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>A-a gradient</td>
<td>22, 232</td>
</tr>
<tr>
<td>A-beta fibers</td>
<td>209</td>
</tr>
<tr>
<td>Abruptio placenta</td>
<td>180</td>
</tr>
<tr>
<td>Acetazolamide</td>
<td>See Diuretics</td>
</tr>
<tr>
<td>Acromegaly</td>
<td>41, 164</td>
</tr>
<tr>
<td>Activated clotting time (ACT)</td>
<td>139</td>
</tr>
<tr>
<td>Acute alcoholic hepatitis</td>
<td>18</td>
</tr>
<tr>
<td>Acute epiglottitis</td>
<td>196</td>
</tr>
<tr>
<td>Acute herpetic neuralgia</td>
<td>211</td>
</tr>
<tr>
<td>Acute idiopathic polyneuritis</td>
<td>See Guillain-Barré syndrome</td>
</tr>
<tr>
<td>Acute respiratory failure</td>
<td>Intubation criteria</td>
</tr>
<tr>
<td>Addison’s disease</td>
<td>See Hypoaldosteronism</td>
</tr>
<tr>
<td>A-delta fibers</td>
<td>209</td>
</tr>
<tr>
<td>Adenosine</td>
<td>10</td>
</tr>
<tr>
<td>Adhesive arachnoiditis</td>
<td>221</td>
</tr>
<tr>
<td>Adrenal gland</td>
<td>43</td>
</tr>
<tr>
<td>Adrenal hypersecretion</td>
<td>44</td>
</tr>
<tr>
<td>Adrenocorticotropic hormone (ACTH)</td>
<td>See Adrenal hypersecretion</td>
</tr>
<tr>
<td>Adult Respiratory Distress Syndrome</td>
<td>35</td>
</tr>
<tr>
<td>Airway fire</td>
<td>225</td>
</tr>
<tr>
<td>Airway laser surgery</td>
<td>224</td>
</tr>
<tr>
<td>ALA synthetase</td>
<td>66</td>
</tr>
<tr>
<td>Allodynia</td>
<td>209</td>
</tr>
<tr>
<td>Alpha agonists</td>
<td>79</td>
</tr>
<tr>
<td></td>
<td>Clonidine</td>
</tr>
<tr>
<td></td>
<td>Fenoldopam</td>
</tr>
<tr>
<td></td>
<td>Methyladrenalectomy</td>
</tr>
<tr>
<td>Alpha blockers</td>
<td>79</td>
</tr>
<tr>
<td>Alpha phase metabolism</td>
<td>97</td>
</tr>
<tr>
<td>Alpha stat</td>
<td>230</td>
</tr>
<tr>
<td>Alpha-1 glycoprotein</td>
<td>97</td>
</tr>
<tr>
<td>Alprostadil</td>
<td>181, See Prostaglandins</td>
</tr>
<tr>
<td>Amiloride</td>
<td>See Diuretics</td>
</tr>
<tr>
<td>Aminocaproic acid</td>
<td>139</td>
</tr>
<tr>
<td>Aminocaproic acid (EACA)</td>
<td>74</td>
</tr>
<tr>
<td>Amiodarone</td>
<td>78</td>
</tr>
<tr>
<td>Amphetamines</td>
<td>83</td>
</tr>
<tr>
<td>Amrinone</td>
<td>78</td>
</tr>
<tr>
<td>Anesthesia circuits</td>
<td>See Circuits</td>
</tr>
<tr>
<td>Anesthesia machine</td>
<td>Carbon dioxide removal</td>
</tr>
<tr>
<td></td>
<td>Flow meters</td>
</tr>
<tr>
<td></td>
<td>Gas cylinders</td>
</tr>
<tr>
<td>Mechanical ventilators</td>
<td>254</td>
</tr>
<tr>
<td>Negative pressure test</td>
<td>253</td>
</tr>
<tr>
<td>Positive pressure test</td>
<td>253</td>
</tr>
<tr>
<td>Scaevenging system</td>
<td>257</td>
</tr>
<tr>
<td>Vapor pressure</td>
<td>253</td>
</tr>
<tr>
<td>Vaporizers</td>
<td>253</td>
</tr>
<tr>
<td>Ankle block</td>
<td>215</td>
</tr>
<tr>
<td>Anterior Pituitary</td>
<td>See Pituitary</td>
</tr>
<tr>
<td>Anticholinergics</td>
<td>84</td>
</tr>
<tr>
<td>Anticholinesterase</td>
<td>85</td>
</tr>
<tr>
<td>Edrophonium</td>
<td>85</td>
</tr>
<tr>
<td>Neostigmine</td>
<td>85</td>
</tr>
<tr>
<td>Physostigmine</td>
<td>85</td>
</tr>
<tr>
<td>Pyridostigmine</td>
<td>85</td>
</tr>
<tr>
<td>Anticoagulation guidelines</td>
<td>220</td>
</tr>
<tr>
<td>Antidiuretic hormone</td>
<td>41</td>
</tr>
<tr>
<td>Anti-thrombin III</td>
<td>138</td>
</tr>
<tr>
<td>Aortic aneurysm</td>
<td>131</td>
</tr>
<tr>
<td>Arterial line placement</td>
<td>131</td>
</tr>
<tr>
<td>Cross-clamp management</td>
<td>132</td>
</tr>
<tr>
<td>Aortic dissection</td>
<td>132</td>
</tr>
<tr>
<td>Retrograde dissection</td>
<td>133</td>
</tr>
<tr>
<td>Aortic regurgitation</td>
<td>116</td>
</tr>
<tr>
<td>Aortic stenosis</td>
<td>117</td>
</tr>
<tr>
<td>Aortic stretch receptors</td>
<td>237</td>
</tr>
<tr>
<td>APGAR</td>
<td>182</td>
</tr>
<tr>
<td>Apnea monitoring</td>
<td>269</td>
</tr>
<tr>
<td>Apneic oxygenation</td>
<td>28</td>
</tr>
<tr>
<td>Aprotinin</td>
<td>139</td>
</tr>
<tr>
<td>Arnold Chiari malformation</td>
<td>164, 195</td>
</tr>
<tr>
<td>Artery of Adamkiewicz</td>
<td>165</td>
</tr>
<tr>
<td>Aspirin</td>
<td>139</td>
</tr>
<tr>
<td>Asymmetric septal hypertrophy</td>
<td>123</td>
</tr>
<tr>
<td>Atlanto-axial subluxation</td>
<td>71</td>
</tr>
<tr>
<td>Atrial stretch receptors</td>
<td>30</td>
</tr>
<tr>
<td>Augmented alveolar ventilation</td>
<td>88</td>
</tr>
<tr>
<td>Automatic implantable cardiac defibrillators (AICD)</td>
<td>125</td>
</tr>
<tr>
<td></td>
<td>Self monitoring system</td>
</tr>
<tr>
<td>Awake fiberoptic intubation</td>
<td>223</td>
</tr>
<tr>
<td>Axillary block</td>
<td>212</td>
</tr>
<tr>
<td>Axonotmesis</td>
<td>214, 247</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>B</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Barbiturate coma</td>
<td>99</td>
</tr>
<tr>
<td>Barbiturates</td>
<td>99</td>
</tr>
<tr>
<td>Methohexital</td>
<td>100</td>
</tr>
</tbody>
</table>
Porphyria · 99
Thiopental · 99
Beck’s triad · 14
Beckwith-Wiedemann syndrome · 193
Benzodiazepines · 98
Beta blockers · 79
Labetolol · 79
Beta phase metabolism · 97
Bicarbonate therapy · 232
in pediatrics · 189
Bi-spectral index (BIS) · 154
Bleomycin · 46
Blood gas analysis · 230
Acute metabolic acidosis · 231
Acute metabolic alkalosis · 231
Acute respiratory acidosis · 230
Anion gap · 231
Chronic metabolic acidosis · 231
Chronic metabolic alkalosis · 231
Chronic respiratory acidosis · 231
Henderson Hasselbalch · 230
Metabolic anion gap acidosis · 231
Bohr effect · 26, 233
Brachial plexus · 205
Brain death criteria · 147, 154
Brainstem auditory evoked potentials (BAEP) · 174
Breach presentation · 177
Bretylium · 78
Bronchopleural fistula · 130
Bronchopulmonary dysplasia · 194
Burns · 36
  Curling ulcer · 37
  Parkland formula · 36
  Rule of nines · 36
Butorphanol · 177

C
Calcium channel blockers · 80
Dantrolene · 80
Nicardipine · 80
Nifedipine · 80
Nimodipine · 80
Verapamil · 80
Canal of Schlemm · 144
Carbon dioxide
  Systemic and pulmonary effects · 233
Carbon dioxide analysis · 268
Carbon monoxide poisoning · 38
Carbonic anhydrase inhibitors · See Diuretics
Carboxyhemoglobinemia · 38, 49, 270
Carcinoid tumor · 46
  Carcinoid syndrome · 46
Cardiac markers · 12
Cardiac stress test · 10, 12
  Dipyridamole · 12
  Stress EKG · 12
  Stress thallium · 12
Cardiac tamponade · 14
Cardiac transplantation · 15
Cardiopulmonary bypass · 119
  Off pump problems · 120
  Pump associated complications · 119
  Roller pump · 119
Carotid baroreceptors · 28, 135
Carotid bodies · 38, 134, 233
Carotid endarterectomy (CEA) · 133
  EEG changes · 134
  Regional block · 134
  Vascular integrity · 134
Carotid equina syndrome · 221
Causalgia (CRPS2) · 210
Celiac plexus block · 217
Cell saver device · 142
Central anticholinergic syndrome · 84
  Phystostigmine · 85
Central pontine myelinolysis · 235, See TURP syndrome
Central receptors · 28
Central venous pressure monitoring · 272
  Waveform interpretation · 272
Cerebral aneurysm · 162
  Hunt Hess classification · 162
  Hydrocephalus · 163
  Rebleeding · 163
  Triple H therapy · 162
  Vasospasm · 162
Cerebral autoregulation · 151
Cerebral blood flow · 150, 166
  CMRO₂ · 150
  Intracerebral steal · 150
  Intravenous agent influences · 152
  Inverse steal · 150
  PaCO₂ · 150
  PaO₂ · 150
  Volatile anesthetic influences · 153
Cerebral palsy · 164
Cerebral physiology pearls · 169
Cervical plexus block · 216
Cervical spine injury · 172
  Spinal shock · 172
Cesarean section · 178
Chassaignac tubercle · 216
Choroidal blood volume · 144
Chronic obstructive pulmonary disease (COPD) · 59
  Asthma · 59
cAMP · 59
Chronic bronchitis · 59
Emphysema · 59
Pulmonary function tests · 60
Treatment · 61
Chronic renal failure · 31
Chvostek sign · 42
Cimetidine · 228
Circle of Willis · 165
Circuits
Closed · 264
Open · 263
Semi-closed (Circle) · 264
Semi-open (Mapleson) · 263
Cirrhosis · 18
Citrate toxicity · 52
Cleft palate and cleft lip · 193
Clonidine · 82
CO₂ response curve · 27
Cobb’s angle · 170
Cocaine · 50
Compound A · 92, 96
Congenital diaphragmatic hernia (CDH) · 195
Conivaptan · 41
Conn’s disease · See Hyperaldosteronism
Cooley’s anemia · 48
Coronary perfusion · 10
Coronary steal syndrome · 91, 95, See Adenosine
Corticotrophin releasing hormone · 43
Cromolyn sodium · 61
Croup · 197
Cryoprecipitate · 140
Cushing response · 146, 168
Cushing’s disease · See Adrenal hypersecretion
Cushing’s triad · 168
Cyanide · 77, 82
Amyl nitrate · 17, 77
Hydroxocobalamin · 17
Rhodanase · 77
Sodium nitrate · 77
Thiosulfate · 17
Toxicity treatment · 83
Cyanide · See Sodium nitroprusside
Cyclosporine · 32
Cystic fibrosis · 39
Cytal · 73

Hyperglycemic “Diabetic” Ketoacidosis (DKA) · 45
Hyperosmolar hyperglycemic non-ketotic coma · 45
Hypoglycemia · 40
Insulin aspart · 40
Lente · 40
Lispro · 40
NPH · 40
Osmotic diuresis · 40
Ultralente · 40
Diabetic ketoacidosis · 40
Diazepam
Active metabolite · 98
Diffusion hypoxia · 88
Digitalis · See Digoxin
Digoxin · 77, 82
Toxicity · 82
Disseminated intravascular coagulopathy (DIC) · 141
Diuretics · 80, 114
Dobutamine · 78
Dopamine · 78
Double lumen tube · 128
Down lung syndrome · 129
Down’s syndrome · 196
Doxorubicin · 46, 84
Droperidol · 86
Drug eluting stents · 14
Drug infusion shortcuts · 76
Ductus arteriosus · 198
Ductus venosus · 198

E

Ebstein’s anomaly · 273
Echothiophate · 145
Eclampsia · 178
Eisenmenger syndrome · 191
EKG interpretation · 12
EKG monitoring · 275
Electrocautery · 267
Electroconvulsive therapy (ECT) · 155
Electroencephalogram (EEG) · 154
Electromechanical dissociation · 13
Ephedrine · 81
Guanethidine · 81
Tachyphylaxis · 81
Epidural anesthesia · 219
Narcotic effects · 219
Taylor approach · 220
Epinephrine · 78, 81
MAO · 81
Tyrosine hydroxylase · 81
Esophagectomy · 46
Etomidate · 101

D

DDAVP · 140
Demeclocycline · 41, See Diuretics
Desmopressin · 41
Dextran · 148
Diabetes insipidus · 41, 163
Diabetes mellitus · 40, 45
Hyperglycemia · 40
Adrenocortical suppression · 101
Metabolism · 101
Extracorporeal membrane oxygenation (ECMO) · 195, 260
Extracorporeal shockwave lithotripsy (ESWL) · 74
Extubation criteria · 143

F
Familial dysautonomia · 164
Fat embolism · 147, 239
Femoral nerve block · 215
Fenfluramine-Phenteramine · See Amphetamines
Fetal blood gas · 184
Fetal heart rate · 181
Early deceleration · 182
Late deceleration · 182
Variable deceleration · 182
Fetal maturity assessment · 179
First order kinetics · 97
First pass metabolism · 97
Flow-volume loops · 24, 63
Fresh frozen plasma · 139
Furosemide · See Diuretics

G
G6PD deficiency · 49
GABA · 209
Gasserian ganglion · 210
Gastrochisis · 193
Geriatric physiology · 47
Glasgow coma score · 146
Glossopharyngeal nerve · 208
Glutamate · 209
Glycine · 73, 209
Ammonia toxicity · 73
Visual evoked potentials · 73
Graves’ disease · 42
Growth hormone · 41, 164
Guillain-Barré syndrome · 156

H
Haldane effect · 26, 233
Halothane hepatitis · 18
Heart blocks · 126
Heinz bodies · 49
Heliox · 248
HELLP syndrome · 179
Hemophilia A · 138
Hemophilia B · 138
Heparin · 138
Heparin induced thrombocytopenia · 139
Hepatic blood flow · 18, 51
Hepatorenal syndrome · 50
Hereditary angioedema · 227
Hemostarch · 148
High frequency jet ventilation · 260
Hoffman elimination · 110
Horner’s syndrome · 214
Hyperaldosteronism · 43
Hypercalcemia · 236, See Hyperparathyroidism
Hyperkalemia · 235
Hypermagnesemia · 236
Hypernatremia · 235
Hyperparathyroidism · 43
Etidronate · 43
Plicamycin · 43
Hypertension · 249
Hyperthyroidism · 41
Hypoaldosteronism · 44
Hypocalemia · 188, 236
Hypoglycemia · 188
Hypokalemia · 235
Hyponatremia · 235
Hypothyroidism · 42
Hypoxia · 129
Management · 248
Oxygen consumption · 246
Oxygen content and delivery · 246
Oxygen diffusion and transfer · 245
Reduced oxygen intake · 245
Hypoxic pulmonary vasoconstriction · 21, 129
Hypoxic ventilatory drive · 92

I
Idiopathic hypertrophic subaortic stenosis (IHSS) · 123
Infraclavicular block · 212
Inhalation induction
Concepts · 88
Pediatrics · 89
Intercostal nerve block · 214
Interscalene block · 213
Intra-aortic balloon pump · 120
Intracardiac shunts · 191
Eisenmenger syndrome · 191
Patent ductus arteriosus (PDA) · 192
Tetralogy of fallot · 191
Transposition of great vessels · 191
Intracerebral pressure (ICP) · 151
    Mannitol · 151
Intracranial pressure · 167
    Measurement of · 168
    Treatment for elevated ICP · 168
Intraocular pressure · 144
Invasive blood pressure monitoring · 271
    Damping and natural frequency · 271
Isoproterenol · 79

K
Kent’s bundle · 13
Ketamine · 100
    Norketamine · 100
King-Denborough syndrome · 53
Korotkoff sounds · 271
Kussmaul’s sign · 14

L
Lambert-Beer law · 270
Lambert-Eaton syndrome · 161
    Comparison to myasthenia gravis · 161
Laryngospasm · 224
Latex · 226
    AlaStat assay · 226
    RAST test · 226
L-Dopa · 86
Lenegre’s disease · 13, 126
Line isolation monitor · 266
Lithium · 41, 85, 155
Liver transplantation · 52
Local anesthetics · 107
    Duration · 107
    Methemoglobinemia · 108
    Onset · 107
    Potency · 107
    Toxicity · 108
Loop diuretics · See Diuretics
Low molecular weight heparin (LMWH) · 139
Lumbar plexus · 207
Lumbar sympathetic block · 216
Lung isolation · 128
Lung zones · 20
    Dead space · 21
    Shunt · 21

M
Macroshock · 266
Magnesium toxicity · 179
Malignant hyperthermia · 53
    Dantrolene · 53
    Triggers · 53
    Mannitol · 87
Masseter spasm · 55
Mechanical ventilation · 259
    Complications · 261
    Pressure cycled · 260
    Volume cycles · 259
Meckel’s cave · 210
Meconium aspiration · 187, 198
Mediastinoscopy · 130
Mendelson syndrome · 228
Meningomyelocele · 195
Mental status changes · 250
Metanephrines · See Pheochromocytoma
Methemoglobinemia · 56, 270
Methimazole · 42
Methionine synthetase · 181
Methylmethacrylate · 239
Methylxanthines · 62
Midazolam
    Active metabolite · 98
Milrinone · 78
Minimum alveolar concentration (MAC) · 89
Mitomycin · 46
Mitrail regurgitation · 116
Mitrail stenosis · 117
Mnemonic
    BLUES PD · 84, 160
    C-BIG-K · 45
    CLOSE · 23, 57
    COLD · 200
    Cold Ice-skaters Always Enjoy Hot Drinks · 148
    C-TOP · 249
    Dogs In Heat Go Nuts · 80, 185
    Dorky Residents Have Very Sexy Eyeglasses · 263
    Drunk Cows Avoid Sex · 263
    Hairy Armpits Have Lousy Hygiene · 22
    Hunters Have Active Dogs · 28
    Las Vegas has Horney Dudes · 259
    MATES · 68
    Men Love Using Paper Shredders Excessively · 231
    MOP THIS · 250
    NG SOAP · 24, 57
    PaSeR · 124
    Personal Sacrifice Pushes Soldiers · 216
    Really Funny Looking · 116
    SHADE · 148, 249
    SHOP MD · 249
    Silky Smooth Skin · 179
    Smoking Adolescents Avoid Cops · 22
    Snakes Sing Terribly · 117
    VINDICATE · 19
    Monoamine oxidase inhibitors (MAOI) · 83
    Motor evoked potentials (MEP) · 174

[16]
Muscular dystrophy · 157
Myasthenia gravis · 159
Myasthenic syndrome · 130
Myoclonus · 101
Myofascial pain syndrome · 210
Myotonic dystrophy · 157
Myotonia congenita · 158
Myotonia dystrophica · 157
Paramyotonia · 158
Myxedema coma · 43

N

Nalbuphine · 177
Narcotics
   Meperidine · 83
   Nasotracheal intubation · 223
   Necrotizing enterocolitis · 194
Neoantigens · 18
Nerve injuries · 247
Neuroleptic malignant syndrome · 55, 86
Neurolytic nerve blocks · 217
Neuromuscular block · 109
   Acetylcholinesterase inhibitors · 109
   Depolarizing agents · 111
   Dibucaine number · 113
   Myasthenia gravis · 112
   Nondepolarizing agents · 110
   Organophosphates · 111
   Phase I and II block · 112
   Potentiation of · 111
   Resistance to · 111
   Sensitivity and resistance table · 113
   Train of four · 109
Neuropraxia · 214, 247
Neurotmesis · 215, 247
Nitropusside · 241
Non-stress test · 179
Norepinephrine · 81
   Reuptake inhibitors · 81
Normetanephrines · See Pheochromocytoma
NSAIDs · 86
   Ketorolac · 87

O

Obesity hypoventilation syndrome · 58
Obstructive lung diseases · 24
Octreotide · See Carcinoid tumor
Oculocardiac reflex · 145
Ohmeda ventilator · 253
Omphalocele · 193

Opioids · 102
   Alfentanil · 104
   Buprenorphine · 104
   Butorphanol · 104
   Fentanyl · 105
   Meperidine · 104
   Morphine · 103
   Nalbuphine · 104
   Nalorphine · 104
   Naloxone · 104
   Naltrexone · 104
   Pentazosine · 104
   Remifentanil · 105
   Sufentanil · 105
Osmoreceptors · 41
Osmotic diuretics · See Diuretics
Oxygen concentration monitoring · 270
Oxyhemoglobin dissociation curve · 26
Oxytocin stress test · 179

P

Pacemaker
   Indications · 124
   Nomenclature · 124
   Troubleshooting · 124
Packed red blood cells (PRBC) · 140
   Preservative solutions · 140
Paracervical block · 177
Parathyroid · 43
Parkinson’s disease · 65, 86
   Dopamine antagonists · 65
   Levodopa · 65
Pediatrics
Airway considerations · 200
   Anesthetic considerations · 201
Cardiopulmonary physiology · 198
   Caudal anesthesia · 203
   Fetal physiology · 198
   Fluid management · 200
   Renal physiology · 201
   Temperature regulation · 200
Peripheral chemoreceptors · 28
Peripheral nerve blocks · 214
   Bier block · 214
   pH stat · 230
Phantom limb pain · 210
Pharmacodynamics · 97
Pharmacokinetics · 97
Phenoxybenzamine · See Pheochromocytoma
Phenylalanine · 81
Phenytoin · 86
Pheochromocytoma · 44
Pickwickian syndrome · 58
Pierre Robin syndrome · 196
Pituitary · 41
Placenta acreta · 180
Placenta drug transfer · 80
Placenta previa · 180
Plasma cholinesterase · See Pseudocholinesterase
Plasma esterase · 101
Platelets · 140
Poiseuille’s equation · 167
Porphyria
    Treatment · 66
Positive end expiratory pressure (PEEP) · 260
Post herpetic neuralgia · 211
Posterior fossa craniotomy · 163
    Venous air embolism · 163
Posterior pituitary
    Antidiuretic hormone · 163
Posterior Pituitary · See Pituitary
Potassium sparing diuretics · See Diuretics
Pre-eclampsia · 178
Pregnancy induced hypertension (PIH) · 178
Prematurity · 189
Procainamide · 78
Propofol · 101
Propylthiouracil · 42
Prostaglandins · 87
    Alprostadil · 87
    PDA patency · 87
Pseudocholinesterase · 51, 68
    Dibucaine test · 68
    Drugs metabolized by · 51
    MAO inhibitors · 84
    Trimethaphan · 81
Psoas compartment block · 215
Pudendal block · 177
Pulmonary artery catheter and monitoring · 273
    Mixed venous oxygen saturation · 274
Pulmonary function test (PFT) · 127
    Split lung function · 128
    Unilateral pulmonary artery occlusion test · 128
Pulmonary hypertension · 28
Pulmonary vascular resistance · 191
Pulse oximetry · 270
Pulsus paradoxus · 14, 133
Pyloric stenosis · 192
Recumbent block · 145
Reye syndrome · 167
Rheumatoid arthritis · 71
    Rheumatoid nodules · 71
Rule of 3s · 169
Rule of 50s · 169
Sacral plexus · 207
Sciatic nerve block · 215
Scoliosis · 170
    Assessment of · 171
    Harrington rod · 171
Serotonin syndrome · 84
Shunt fraction · 21
SIADH · 41, 164
Sickle cell disease · 48
Small cell lung carcinoma · 41
Smoking · 28
Smoking cessation · 38
Sodium bicarbonate · 79
Sodium nitroprusside · 17, 77, 82
Somatosensory evoked potential monitoring (SSEP) · 174
Spinal anesthesia · 218
Spinal cord blood flow · 165
Spinal headache · 218
Spirometry · 23
Spironolactone · See Diuretics
Stellate ganglion block · 216
Steroids · 61
Stickler syndrome · 196
Subarachnoid hemorrhage (SAH) · 162
Substance P · 209
Sulfur hexafluoride (SF₆) · 144
Superior laryngeal nerve · 208
Supine hypotension syndrome · 184
Supraclavicular block · 213
Syringomyelia · 164
Systemic lupus erythematosus · 72
    Aseptic necrosis · 72
Tetany · 236
Thalassemia · 48
The concentration effect · 88
The second gas effect · 88
Thermodilution · 274
Thiazide diuretics · See Diuretics
Thoracic spine injury · 172
    Autonomic hyperreflexia · 173
    Flaccid paralysis · 172